Iranian journal of Pediatric Hematology and Oncology
Iranian journal of Pediatric Hematology and Oncology
Iran J Ped Hematol Oncol
Medical Sciences
http://ijpho.ssu.ac.ir
1
admin
2008-8892
2228-6993
8
7
14
8888
13
en
jalali
1404
10
1
gregorian
2026
1
1
16
1
online
1
fulltext
en
Aberrant Immunophenotype in Childhood Acute Lymphoblastic Leukemia: Overall Survival and Disease-Free Survival up to 18 Months after Diagnosis
انکولوژی
Oncology
پژوهشي
Research
<div style="text-align: justify;"><span style="font-size:12px;"><span style="font-family:Tahoma;"><b><span style="color:#231f20"><span style="letter-spacing:-.3pt">Background: </span></span></b><span style="color:#231f20"><span style="letter-spacing:-.3pt">Aberrant immunophenotype, characterized by the expression of lineage-inappropriate antigens on leukemic blasts, is associated with early relapse and a poor survival rate in Acute Lymphoblastic Leukemia (ALL). Early relapse gives a bad prognosis for ALL. This study evaluated the association between aberrant immunophenotype and Overall Survival (OS) and Disease-Free Survival (DFS) up to 18 months following the diagnosis of ALL. </span></span><br>
<b><span style="color:#231f20"><span style="letter-spacing:-.3pt">Materials and Methods: </span></span></b><span style="color:#231f20"><span style="letter-spacing:-.3pt">A retrospective cohort study was conducted to identify aberrant immunophenotype in 156 patients under 18 years of age with ALL. In this study, done at a tertiary level hospital, OS and DFS were analyzed using the Kaplan-Meier method, the Breslow test and a Cox regression model, with hazard ratios to determine the variables associated with mortality and relapse over an 18-month follow-up period.</span></span><br>
<b><span style="color:#231f20"><span style="letter-spacing:-.3pt">Results: </span></span></b><span style="color:#231f20"><span style="letter-spacing:-.3pt">The mean age at diagnosis was 6.5 years, and 57% of the patients were male. Aberrant immunophenotype was expressed in 87 patients. After 18 months of follow-up, 41 patients had died. The CD123 antigen was mostly associated with relapses (p=0.010). CD66c and CD123 co-expression decreased OS (p=0.040) and DFS (p=0.003). The univariate analysis demonstrated that CD66c and CD123 co-expression (p=0.005), single CD123 expression (p=0.001), and positive Measurable Residual Disease (MRD) (p=0.001) increased the risk of relapse. In a multivariable analysis, only risk stratification and MRD remained as independent predictors of OS and DFS.</span></span><br>
<b><span style="color:#231f20"><span style="letter-spacing:-.3pt">Conclusion: </span></span></b><span style="color:#231f20"><span style="letter-spacing:-.3pt">CD66c and CD123 co-expression was associated with decreased OS and DFS and a higher risk of relapse. However, this association did not remain significant in the multivariate model, indicating that it is not an independent prognostic factor. Nonetheless, isolated CD123 expression was linked to positive MRD and an increased risk of relapse. These observations provide clinically relevant preliminary insights, particularly in settings with survival disparities. These require confirmation in larger cohorts with extended follow-up and integrated molecular data</span></span></span></span></div>
Childhood ALL, Disease-Free Survival, Immunophenotyping, Leukemia, Prognosis
716
728
http://ijpho.ssu.ac.ir/browse.php?a_code=A-10-1219-1&slc_lang=en&sid=1
Betzayda
Valdez Garibay
Betzayda
Valdez Garibay
valdezbetzy@gmail.com